| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/27/2006 | WO2006077161A1 Vaccines based on the use of mv |
| 07/27/2006 | WO2006077101A2 Ager-peptides and use thereof |
| 07/27/2006 | WO2006050041A3 Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis |
| 07/27/2006 | WO2006044643A3 Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| 07/27/2006 | WO2006037807A3 Identification of regions of apical membrane antigen 1 of apicomplexan parasites suitable for targeting by vaccines and drugs by derivation and analysis of the three-dimensional structure |
| 07/27/2006 | WO2006037029A3 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 07/27/2006 | WO2006036817A3 Fungal variants and uses thereof |
| 07/27/2006 | WO2006036568A9 Antibody buffering of a ligand in vivo |
| 07/27/2006 | WO2006031363A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 07/27/2006 | WO2006026689A3 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| 07/27/2006 | WO2006020898A3 Methods of screening for inhibitors and compositions thereof for treating or preventing mycobacterium tuberculosis infection |
| 07/27/2006 | WO2006020730A3 Ileitis diagnostic assay |
| 07/27/2006 | WO2006015373A3 Antibodies to dkk-1 |
| 07/27/2006 | WO2006008076A3 Methods and agents stimulating the immune response |
| 07/27/2006 | WO2005114206A3 Diagnostics and therapeutics for diseases associated with serotonin 5-ht5a receptor (5ht5a) |
| 07/27/2006 | WO2005113589A3 Modified antigen-presenting cells |
| 07/27/2006 | WO2005110459A3 Method of inducing immunity against stratum corneum chymotrytic enzyme |
| 07/27/2006 | WO2005097187A3 Methods of preventing uvb-induced skin damage |
| 07/27/2006 | WO2005092922A3 Antigen of the pm-2 antibody and use thereof |
| 07/27/2006 | WO2005060675A3 Novel spliced 5-ht1a receptors and methods, kits, and uses relating thereto |
| 07/27/2006 | WO2004058184A3 Anti-ngf antibodies and methods using same |
| 07/27/2006 | WO2004048432A3 Preparation of polyphosphazene microspheres |
| 07/27/2006 | WO2004034988A3 Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors |
| 07/27/2006 | WO2004005883A3 Secreted and cytoplasmic tumor endothelial markers |
| 07/27/2006 | US20060167232 Antibody against n-terminal peptide or c-terminal peptide of gpc3 solubilized in blood |
| 07/27/2006 | US20060167227 Truncated tau proteins |
| 07/27/2006 | US20060166923 Immune stimulating composition comprising bacterial chromosomal DNA fragments having methylated CpG sequences and non-toxic lipopolysaccharides |
| 07/27/2006 | US20060166912 Use of cytochrome p450 enzyme cyp2w1 as a drug target for cancer theraphy |
| 07/27/2006 | US20060166911 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a) |
| 07/27/2006 | US20060166872 Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia |
| 07/27/2006 | US20060166863 Inhibitor and stimulator of stem cell proliferation and uses thereof |
| 07/27/2006 | US20060166344 Bacterial outer memberane vesicles |
| 07/27/2006 | US20060166325 Glial cell line-derived neurotrophic factor receptor |
| 07/27/2006 | US20060166284 used to form a non-thrombogenic coating on the surface of a medical device; antibodies bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone |
| 07/27/2006 | US20060166255 Methods of using 48149, a human Aminopeptidase family member |
| 07/27/2006 | US20060166254 Protocol for optimizing purification of enzymatically active human telomerase |
| 07/27/2006 | US20060166217 Genetic marker for coronary artery disease |
| 07/27/2006 | US20060166212 Breast specific protein expressed in cancer and methods of use thereof |
| 07/27/2006 | US20060166189 Methods for detecting invasion of a cell |
| 07/27/2006 | US20060165805 Magnetic pole matrices useful for tissue engineering and treatment of disease |
| 07/27/2006 | US20060165732 Fungal antigens and eosinophil activity |
| 07/27/2006 | US20060165731 Vaccines |
| 07/27/2006 | US20060165730 Polysaccharide and glycoconjugate vaccines |
| 07/27/2006 | US20060165729 Protein from photobacterium damselae and use thereof |
| 07/27/2006 | US20060165728 Campylobacter glycans and glycopeptides |
| 07/27/2006 | US20060165727 Vaccine; inducing an immune response; infectious diseases, which can be caused by more than one strain, clade, variant, subtype or serotype of infectious disease causing microorganism; reliable vaccination against all Dengue virus serotypes |
| 07/27/2006 | US20060165726 Remedies with the use of hollow protein nanoparticles presenting growth factor or the like |
| 07/27/2006 | US20060165725 HBV drug resistance drug resistance detection methods |
| 07/27/2006 | US20060165724 Method of producing infectious reovirus |
| 07/27/2006 | US20060165723 Nucleic acid sequences encoding proteins capable of associating into a virus-like particle |
| 07/27/2006 | US20060165722 Peptides for delivery of mucosal vaccines |
| 07/27/2006 | US20060165719 Plasmodium falciparum antigens and methods of use |
| 07/27/2006 | US20060165718 Immunizing compositions and methods of use |
| 07/27/2006 | US20060165717 DCchol in newborns |
| 07/27/2006 | US20060165716 Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| 07/27/2006 | US20060165715 Gp41 inhibitor |
| 07/27/2006 | US20060165714 Peptides for vaccination against human CMV |
| 07/27/2006 | US20060165713 Vaccine |
| 07/27/2006 | US20060165712 can catalyze site-selective acyl transfer |
| 07/27/2006 | US20060165711 Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
| 07/27/2006 | US20060165710 Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
| 07/27/2006 | US20060165709 stimulate T cytotoxic lymphocytes in a mammal |
| 07/27/2006 | US20060165708 Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
| 07/27/2006 | US20060165707 Substances |
| 07/27/2006 | US20060165706 Antibodies against CTLA4 and uses therefor |
| 07/27/2006 | US20060165705 Immunoselective targeting agents and methods of use thereof |
| 07/27/2006 | US20060165704 Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody |
| 07/27/2006 | US20060165703 Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis |
| 07/27/2006 | US20060165702 treating cancer in humans comprising administering oncogene monoclonal antibodies, such as pertuzumab |
| 07/27/2006 | US20060165701 Agents for the diagnosis and treatment of tumors that expose alerted proteins on the cell surface |
| 07/27/2006 | US20060165700 Cancer therapy using whole glucan particles and antibodies |
| 07/27/2006 | US20060165699 Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role |
| 07/27/2006 | US20060165698 Polypeptide from ink of molluscs; L-lysine or L-arginine oxidase capable of producing hydrogen peroxide in tumor tissues with less toxic side effects upon normal cells |
| 07/27/2006 | US20060165697 comprising a homeopathically potentised form of polyclonal, antibodies to endothelial nitric oxide synthase (NO synthase) |
| 07/27/2006 | US20060165696 Remedy for spinal injury containing interleukin-6 antagonist |
| 07/27/2006 | US20060165695 Antibody against human insulin-like growth factor |
| 07/27/2006 | US20060165694 Fab fragments and their DNA sequences used for preparation of complete recombinant Anti-Rhesus D antibodies; biodrugs; medical diagnosis |
| 07/27/2006 | US20060165693 treating a patient having cancer |
| 07/27/2006 | US20060165692 Humanized anti-CD3 specific antibodies |
| 07/27/2006 | US20060165691 Humanized anti-CD3 specific antibodies |
| 07/27/2006 | US20060165690 Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies |
| 07/27/2006 | US20060165689 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 07/27/2006 | US20060165688 Remedies for pemphigus containing cd40l antogonist as the active ingredient |
| 07/27/2006 | US20060165687 enhancing an immune response to a vaccine by administering an agent that transiently suppresses the number of CD4+/CD25+/Foxp3+T regulatory cells, or the immunosuppressive function of said T regulatory cell |
| 07/27/2006 | US20060165686 Combining therapies targeting multiple toll-like receptors and use thereof |
| 07/27/2006 | US20060165685 Bispecific anti-erb-b antibodies and their use in tumor therapy |
| 07/27/2006 | US20060165684 T-cell immune response cDNA 7 (TIRC7) antagonist; rheumatoid arthritis; comprising all three complementarity determining regions (CDRs) of the VH and all three complementarity determining regions (CDRs) of the VL variable regions; inhibiting proliferation of peripheral blood mononuclear cells |
| 07/27/2006 | US20060165683 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 07/27/2006 | US20060165682 Humanized antibodies that recognize beta amyloid peptide |
| 07/27/2006 | US20060165681 Antibodies to myelin associated glycoprotein (MAG); neurological diseases/disorders |
| 07/27/2006 | US20060165680 Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors |
| 07/27/2006 | US20060165679 Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2) |
| 07/27/2006 | US20060165678 Measuring changes in level of antigen recognizable by a monoclonal antibody or antigen binding fragment; monoclonal antibody is produced by hybridoma cell line; decreased level indicates a reduced tumor; diagnosis, cell purification |
| 07/27/2006 | US20060165677 recombinant dimer consisting of two IgE-dependent histamine releasing factor (HRF), known as translationally controlled tumor protein(TCTP); for treatment of allergic diseases including asthma and rhinitis or malaria |
| 07/27/2006 | US20060165676 Identification of tsh receptor autoantibodies using affinity-purified antibodies |
| 07/27/2006 | US20060165675 Modulation of mesenchymal cells via iga-receptors |
| 07/27/2006 | US20060165664 Method of inducing an enhanced immune response against hiv |
| 07/27/2006 | US20060165657 Method for delivery of cosmetic by topical application |
| 07/27/2006 | US20060165653 Use of Fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders |
| 07/27/2006 | US20060165651 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |